Recompensation in Alcohol Related Hepatitis

Launched by NINA KIMER · Dec 13, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Recompensation in Alcohol Related Hepatitis," is investigating how stopping alcohol intake affects the liver in people who have alcoholic hepatitis (AH). Researchers want to understand the changes that occur in the liver's functions and metabolism when someone stops drinking, as well as how different therapies can help support this process. The study will look into the healing mechanisms in the liver, the effects of motivational enhancement therapy (a type of counseling to encourage patients to quit drinking), and how the liver processes fats and proteins during recovery.

To be eligible for this trial, participants should have a strong clinical suspicion of alcoholic hepatitis, confirmed by specific blood tests and imaging studies. Individuals aged between 65 and 74 who can provide informed consent are welcome to join. Those who are uncertain about their diagnosis of alcoholic hepatitis, withdraw their consent, or have other serious liver conditions will not be included. Participants will receive standard care along with motivational support during the study. This research is crucial for understanding how to better support liver health in individuals recovering from alcohol-related issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical suspicion of AH, supported by biochemistry (bilirubin 50 mmol/l or higher) and ultrasound or other imaging techniques.
• • Informed written consent.
• Exclusion Criteria:
• • People where the diagnosis of AH is questioned with reasonable doubt.
• • Withdrawal of informed consent.
• • Persons eligible for inclusion where the investigational program is delayed or not initiated within two months after the diagnosis of suspected AH.
• • Persons with hepatocellular carcinoma